Although there is promising preclinical data showing the therapeutic value of marine terpenoids to treat diabetes, through mechanisms such as Nrf2/HO-1 pathway activation, to counteract oxidative tissue injury, there is still a paucity of published research in which the link between preclinical outcomes and their efficacy in humans is made (10). The gene discussed is NFE2L2; the disease is diabetes mellitus.